AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05661084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)
Description: Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.
Study NCT05661084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)
Description: Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.
Study NCT06194045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LC-MUFA oil
Description: 2 x 1 g capsules containing marine oil from North Atlantic fish
Study NCT06194045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 1 g capsules containing corn oil
Study NCT06206889 — intervention group
Intervention type: OTHER
Intervention: NAS
Description: NAS Turkish language validation will be carried out. NAS and CNSI scores will be recorded during the shifts of nurses serving patients in Level 3 intensive care units by the nurse in charge and another independent evaluator, and the correlation between the two scores will be investigated.
Study NCT04774939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous laser ablation
Description: The aim is to combine the significance of for sclerotherapy at the primary EVLA treatment
Study NCT05662163 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIVA
Description: Anesthesia will be maintained with propofol (6-10 mg/kg/hour) and remifentanil (0.1-0.3 μg/kg/min).
Study NCT05662163 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GENERAL ANESTHESIA
Description: Anesthesia will be maintained with sevoflurane (2 ml/min) 50% oxygen and remifentanil (0.1-0.3 μg/kg/min).
Study NCT06363747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet
Description: Optifast is a medically supervised very low-calorie diet (VLCD) diet that safely induces caloric restriction
Study NCT04672291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC (Hiltonol®) or Placebo
Description: The safety cohort (Cohort A) consists of 13 patients who will be randomized to receive 2 cycles of the study drug (N10) or 2 placebo cycles (N3).
Study NCT04672291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC (Hiltonol®) or Placebo
Description: The expansion cohort will receive 3 cycles of therapy. A total of 30 patients will be accrued and randomized 4:1 to receive drug (N=24) or placebo (N=6).
Study NCT05000619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach mailer
Description: Postcard or letter
Study NCT05000619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Humor/Salience
Description: Funny cartoon
Study NCT05000619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doctor's authority
Description: Letter from a doctor
Study NCT05000619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information about benefits of the appointment
Study NCT05574257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is injected at 25-100ug/kg/min (immediately after spinal anesthesia to the end of surgery) to maintain the BIS at 70-80.
Study NCT05574257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is injected at 1-20ug/kg/min (immediately after spinal anesthesia to the end of surgery) to maintain the BIS at 70-80.
Study NCT05812677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study NCT05848934 — intervention group
Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field
Study NCT05848934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Multi dimensional neuropsychological test
Study NCT05357131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis without VR (HYP)
Description: HYP will last for 15 minutes including an induction phase of 5 minutes. The hypnotic audio script Heaven of Peace developped/recorded by Pr. M-E. Faymonville will be used.
Study NCT05687864 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysaccharide superparamagnetic ferric oxide injection
Description: The polysaccharide superparamagnetic ferric oxide injection is a clinical diagnostic reagent
Study NCT05991544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training and Follow-up According to the Neuman Systems Model
Description: Neuman Systems Model (NSM) it presents a holistic approach to patients by including physiological, spiritual, sociocultural and five major developmental variables
Study NCT05573269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FOPE (fish oil + pine extract)
Description: During the experiment period the participants will receive a capsule of pine bark extract (Oligopin® 100mg) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
Study NCT05573269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FO (fish oil +placebo)
Description: During the experiment period the participants will receive a capsule of placebo (maltodextrin + magnesium stearate) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
Study NCT06248047 — intervention group
Intervention type: PROCEDURE
Intervention: uretheroplasty
Description: 4. When the bulb and bulbar urethra are exposed and before further dissection, the bulbar arteries are located using a directional doppler ultrasound stethoscope and a decision is made to sacrifice the artery with the lowest doppler signal to preserve the contralateral best artery. The bulbar urethra is then mobilized, circumferentially dissected and separated distally from the corpus cavernosum up to the penoscrotal angle to gain sufficient length for a tension-free end-to-end anastomosis without detachment of the bulb from the perineal body. If the dissection is not sufficient to bridge the gap,inter-corporal septal separation or even an inferior pubectomy are performed. The scarred tissue is removed completely, the proximal urethral segment is exposed as usual with spatulation of the healthy urethral ends and end-to-end anastomosis of the urethra over a silicon catheter is performed. No dissection is performed contralaterally at the bulb to preserve the artery of that side.
Study NCT05907941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ciNPT
Description: Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system \[V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)\] applied by the operating surgeon in a sterile fashion (Figure 2). The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
Study NCT05907941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Tape Dressings
Description: Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
Study NCT05907941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP Breast Reconstruction
Description: All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice. At the Hamilton sites, we will use 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure. At the London sites, we will use 2-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 3-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 4-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
Study NCT05907941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIEP Breast Reconstruction
Description: All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice. At the Hamilton sites, we will use 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure. At the London sites, we will use 2-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 3-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 4-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
Study NCT04763681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple HOPES Guided, Internet-Delivered, Self-Help Intervention
Description: Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson \& Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
Study NCT06626919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anito-cel
Description: Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain
Study NCT06626919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Lymphodepletion regimen
Description: Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion
Study NCT05086211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprioceptive neuromuscular facilitation
Description: Each session including three proprioceptive neuromuscular facilitation techniques:~Balance training exercises,participants will be treated for 20 minutes with PNF techniques that included;Rhythmic initiation, slow reversal techniques practiced with D1 and D2 pattern in lower limb,repeated contraction and Resisted PNF.The Technique will be performed for 3 days per week in same order on all subjects.
Study NCT05086211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pertubation based balance training
Description: Each session will include a 5-10min warm-up,voluntary tasks intended to induce internal perturbations,voluntary tasks combined with external perturbations and a 5-10mins cool down.The technique will be performed for 2 sets of 10 repetitions on all subjects
Study NCT06632613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 capsules, low dose
Description: ENN0403 capsules will be orally administered once a day for 5 consecutive days at low dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
Study NCT06491901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PS was given according to lung ultrasound score
Description: If the lung ultrasound confirms RDS and LUS is more than 8, a full dose of PS will be promptly administered at 200 mg/kg (Poractant Alfa, Curosurf®). If the lung ultrasound does not indicate RDS or if LUS is 8 or less, clinical monitoring will continue. Should the clinical criteria for NRDS be met, a full dose of PS will be administered at 200 mg/kg (Poractant Alfa, Curosurf®). In terms of the administration method, less-invasive surfactant administration (LISA) will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube.
Study NCT06491901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PS was given according to clinical criteria
Description: In cases where clinical diagnosis confirms NRDS, PS will be administered at a dosage of 200 mg/kg (Poractant Alfa, Curosurf®). LISA will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube. If clinical manifestations do not meet the diagnosis of NRDS, PS will not be administered.
Study NCT06632613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403 capsules, high dose
Description: ENN0403 capsules will be orally administered once a day for 5 consecutive days at high dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the placebo capsules will be administrated through a nasogastric tube/oral gastric tube.
Study NCT06632613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules will be orally administered once a day for 5 consecutive days based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
Study NCT06711042 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: functional tests and radiographic analysis
Description: In this observational study, no active interventions or treatments will be administered to the participants. Both groups (Control Group and Experimental Group) will undergo clinical evaluations, including functional tests (WOMAC, Harris Hip Score, Oxford Hip Score, SF-12, TUG) and radiographic analysis (angular measurements). The participants' outcomes will be compared based on their implant placement (within or outside the Functional Safe Zone).
Study NCT06721559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression
Description: Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
Study NCT06721559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telephone friendly visits
Description: Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
Study NCT06729892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine at low dose
Description: Esketamine at low dose was administered(0.2mg· kg-1, 5 ug· kg-1 continuous infusion) and drug dosage was adjusted(propofol and remifentanil) based on the new BIS baseline ( calculated from the pilot study).
Study NCT06729892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new BIS baseline
Description: Close-loop TCI control was under new BIS baseline(calculated from pilot study) in the presence of esketamine at low dose.
Study NCT06729892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: an equivalent dose of saline
Description: An equivalent dose of saline was given and closed-loop control stared.
Study NCT06729892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: original BIS baseline
Description: Drug dosage was adjused under close-loop control based on original BIS baseline.
Study NCT06729892 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: original BIS baseline
Description: Drug dosage was adjused under close-loop control based on original BIS baseline.
Study NCT06762288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Sedation and local anesthesia to the surgical field will be applied as standard procedure and unilateral USG-guided TAP block will be performed to the patients who will undergo TAVİ.
Study NCT06762288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia and sedation
Description: Sedation and local anesthesia to the surgical field will be applied to the patients who will undergo TAVİ.
Study NCT06762288 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Local anesthesia and sedation
Description: Sedation and local anesthesia to the surgical field will be applied to the patients who will undergo TAVİ.
Study NCT06773143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine at low dose
Description: After the induction of general anesthesia, patients in the esketamine group will receive a continuous infusion of esketamine (0.3 mg/kg/h) until the end of the operation.
Study NCT06773143 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (0.9% NaCl)
Description: After the patient's general anesthesia induction is completed, normal saline will be continuously infused until the end of the operation, and the infusion volume is the same as that of the esketamine group.
Study NCT06772051 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Resin composite restoration bonded using universal adhesive in etch and rinse mode (15 seconds etching)
Description: Resin composite restoration bonded using universal adhesive in etch and rinse mode (15 seconds etching)
Study NCT06772051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resin composite restoration bonded using universal adhesive in etch and rinse mode (5 seconds etching)
Description: Resin composite restoration bonded using universal adhesive in etch and rinse mode (5 seconds etching)
Study NCT06772051 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Resin composite restoration bonded using universal adhesive in self-etch mode
Description: Resin composite restoration bonded using universal adhesive in self-etch mode
Study NCT05357131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypnosis with VR (VRH)
Description: The VRH intervention will use the Aqua video session developed by Oncomfort.
Study NCT05332119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR glasses
Description: Patients will watch a virtual world in VR glasses during the painful procedure. They will be able to choose between 3 VR content based on their preferences.
Study NCT05332119 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Patients will not receive distraction during chest drain removal
Study NCT06770153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tensor
Description: balancing will be carried out using the TEMIS DePuy tensioner and carrying out any releases according to the gap-balancing technique
Study NCT06770153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: primary TKA implantation with ligament balancing without use of the tensioner
Study NCT06774287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Karman Line memory strategy training
Description: The memory strategy training consists of six weekly face-to-face treatment sessions. After sessions 3-5, the participant will play 8 levels in total of the Karman Line memory game on their computer or mobile device. In these levels they practice the strategies that are introduced in the face-to-face treatment in a safe digital environment. Also, the Karman Line memory app is provided.
Study NCT06774287 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual contains ten sessions, with nine obligatory sessions supplemented with 1 (of five) non-obligatory sessions. Which non-obligatory sessions is chosen is dependent on the patients treatment goals.
Study NCT06772480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Patients will receive oral thalidomide starting at 50 mg daily, with a weekly increase of 50 mg up to a maximum of 200 mg daily, continued for four months